Peptide Pipeline
Deal · licensing

Novo Nordisk A/S / Emisphere Technologies Inc.

Announced Nov 5, 2007 · closed

Deal terms

Parties
Novo Nordisk A/S · Emisphere Technologies Inc.
Deal type
licensing
Territory
Global
Closing date
Nov 5, 2007
Upfront
$5 million
Milestones
Up to $100 million
Royalties
Low single-digit royalties on net sales
Equity terms
None disclosed
Headline value
Up to $105 million (contingent on milestones)

Assets

View all →

Oral semaglutide

SNAC-enabled oral formulation of semaglutide providing GLP-1 receptor agonism via the gut.

Sources